Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cantargia AB ( (SE:CANTA) ) has shared an announcement.
Cantargia AB announced that the United States Patent and Trademark Office has granted a patent for its antibody nadunolimab, which is in clinical development for treating solid and liquid tumors. This patent, valid until 2035, covers the use of nadunolimab in combination with chemotherapy and/or immunotherapy, particularly for pancreatic ductal adenocarcinoma (PDAC). The patent strengthens Cantargia’s position in the strategically important US market, supporting potential future commercialization. The company has also received Fast Track Designation from the US FDA for nadunolimab in treating metastatic PDAC, highlighting the high unmet medical need and facilitating further development.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program involves the antibody nadunolimab (CAN04), which is being clinically studied in combination with chemotherapy, targeting pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia is listed on Nasdaq Stockholm.
Average Trading Volume: 6,580,672
Technical Sentiment Signal: Hold
Current Market Cap: SEK653.8M
See more data about CANTA stock on TipRanks’ Stock Analysis page.